🇪🇺EU · EMAWithdrawnATC: J07BB01

Celvapan(whole virion influenza vaccine, inactivated containing antigen of strain A/California/07/2009 (H1N1)v)

Disease Outbreaks;Influenza, Human;Immunization

Marketing Authorisation Holder: Nanotherapeutics Bohumil, s.r.o.

EMA Authorisation: 04/03/2009

INN: influenza vaccine (H1N1)v (whole virion, Vero cell derived, inactivated)

Indication

Prophylaxis of influenza caused by A(H1N1)v 2009 virus. Celvapan should be used in accordance with official guidance.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Celvapan — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Celvapan Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.